A 2012 meta-analysis focused specifically on safety issues concluded that the rates of several adverse events were higher with bevacizumab, although the absolute rates of ocular serious adverse events were low with both therapies: ocular adverse events were about 2.8 times as frequent with bevacizumab than with ranibizumab, and "The proportion of patients with serious infections and gastrointestinal disorders was also higher." The authors concluded that " clinicians and patients should continue to carefully weigh-up the benefits and harms when choosing between the two treatment options. We also emphasize the need for studies that are powered not just for efficacy, but for defined safety outcomes based on the signals detected in this systematic review". Biosimilars
Byooviz was approved for medical use in the European Union in August 2021.Ranibizumab-nuna (Byooviz) was approved for medical use in the United States in September 2021.In India, Lupin Limited received marketing approval for its biosimilar of Ranibizumab.On 23 June 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ranivisio, intended for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to macular edema or choroidal neovascularization, and proliferative diabetic retinopathy. The applicant for this medicinal product is Midas Pharma GmbH.
Erythrocyanosis crurum is a skin condition, a variant  of acrocyanosis caused by chronic exposure to cold. See also
Chilblains
List of cutaneous conditions

References
Otto Braun-Falco; G. Plewig; H. H. Wolff; Walter H. C. Burgdorf (2000). Dermatology. Springer Verlag. p. 889. ISBN 3-540-59452-3. James, William D.; Berger, Timothy G.;  et al. (2006). Andrews Diseases of the Skin: Clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0. == External links ==